Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development

Published on January 8, 2026
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retinal diseases, announced it has appointed Laura Cantrell as vice president of corporate strategy and business development, effective immediately. In this role, Cantrell will be responsible for leading Outlook Therapeutics’ business development strategy, including strategic partnerships, licensing opportunities and corporate development initiatives, according to the announcement. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, CEO of Outlook Therapeutics.
Continue reading on website
Other news

Improperly licensed KY optometrists can keep practicing until next year under new regs 

January 7, 2026
Emergency regulations addressing improper licensing of some Kentucky optometrists are criticized as not sufficiently protecting the public.

Kits Eyecare Reports Record Preliminary Q4 and Full 2025 Financial Results

January 8, 2026
VANCOUVER, British Columbia—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider, has reported select preliminary unaudited financial results for its fourth quarter and full year ended December 31, 2025. Key highlights include a 20 percent increase in Q4 revenue year-over-year to approximately $53.9 million, as well as record glasses revenue for Q4 at $8.7 million, up 33